Mayne Pharma Group (MYX.AX) Stock Price
Mayne Pharma Group Price
Revenue has compounded at 51.7% per year over the past 19 years to 383.68 M AUD. Earnings per share have declined at 1.0% per year over the last 16 years. Mayne Pharma Group's net margin stands at 6.4%, up from -179.0% several years earlier. Mayne Pharma Group currently offers a dividend yield of about 21.59%. The payout ratio is around 38% of earnings. The dividend has grown at 5.0% per year over the past 13 years. Analysts set a median price target of 6.22 AUD, implying 146.9% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.
Mayne Pharma Group stock price
Mayne Pharma Group business model & stock analysis
Frequently asked questions about Mayne Pharma Group
Mayne Pharma Group Ltd operates as a pharmaceutical company. Its business model revolves around developing, manufacturing, and distributing branded and generic prescription pharmaceuticals. Mayne Pharma specializes in providing contract development and manufacturing services to customers worldwide. By leveraging its expertise, capabilities, and global reach, Mayne Pharma aims to provide cost-effective and high-quality pharmaceutical products. The company focuses on various therapeutic areas, including cardiology, oncology, women's health, dermatology, and specialty products, catering to the needs of patients and healthcare professionals. Mayne Pharma Group Ltd strives to deliver innovative healthcare solutions and improve patient outcomes through its comprehensive business model.
Mayne Pharma Group Ltd is primarily active in the pharmaceutical industry.
The main competitors of Mayne Pharma Group Ltd in the market include companies like Teva Pharmaceutical Industries Ltd, Fagron NV, and Bio-Pharmaceutics, Inc. These companies operate in the pharmaceutical industry, focusing on generic drugs and specialty pharmaceuticals, similar to Mayne Pharma Group Ltd. By constantly monitoring and analyzing competition, Mayne Pharma Group Ltd strives to maintain its position and market share through strategic business decisions and product innovations.
Mayne Pharma Group Ltd is an Australian pharmaceutical company with a rich history and background. Founded in 1845 as FH Faulding & Co, it has established itself as a reputable player in the industry. In 2015, the company acquired the generic products division of a large U.S. pharmaceutical company, strengthening its global presence. Mayne Pharma Group Ltd specializes in the development and manufacture of generic and specialty pharmaceutical products, focusing on areas such as oncology, dermatology, and women's health. With a commitment to quality and innovation, Mayne Pharma Group Ltd continues to make significant contributions to the healthcare sector globally.
Mayne Pharma Group Ltd has achieved significant milestones in its journey. Some notable accomplishments include the acquisition of Metrics Contract Services, a contract development and manufacturing organization. This strategic move expanded the company's capability to offer a full-service platform for pharmaceutical development and manufacturing. Mayne Pharma also received FDA approval for various generic and specialty pharmaceutical products, further strengthening its market presence in the United States. Additionally, the company successfully launched new products, such as Doryx, in the dermatology segment, and secured international distribution agreements. Mayne Pharma Group Ltd continues to strive for innovative solutions in the pharmaceutical industry to enhance shareholder value and meet patient needs.
Mayne Pharma Group Ltd primarily operates in various countries and regions around the world. The company has a strong presence in Australia, where it is headquartered, and it also has a significant presence in the United States. With a focus on developing, manufacturing, and marketing branded and generic pharmaceutical products, Mayne Pharma Group Ltd serves customers and healthcare professionals in these key markets. Additionally, the company's global reach extends to other regions, including Europe and Asia, where it actively pursues business opportunities and fosters growth. Mayne Pharma Group Ltd's international presence underscores its commitment to delivering high-quality healthcare solutions to a diverse range of patients globally.
Mayne Pharma Group Ltd is a pharmaceutical company that values innovation, integrity, and patient care. With a commitment to developing high-quality, affordable medications, Mayne Pharma Group Ltd aims to improve the health and well-being of individuals worldwide. The company's corporate philosophy revolves around delivering effective solutions through research, development, and manufacturing of pharmaceutical products. Mayne Pharma Group Ltd prioritizes transparency, ethical practices, and collaboration in its operations, ensuring compliance with regulatory standards. By focusing on customer needs and advancing pharmaceutical technologies, Mayne Pharma Group Ltd continues to build a reputation as a trusted and forward-thinking healthcare organization.
Analysts currently set an average price target of 6.22 AUD for the Mayne Pharma Group stock (median: 6.22 AUD), implying +146.9 % versus the latest price. The consensus is based on 5 analyst ratings.
5 analysts currently rate the Mayne Pharma Group stock: 4 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the Mayne Pharma Group share trades at 1.57 EUR (2.52 AUD).
The Mayne Pharma Group share (MYX.AX) is listed on 5 stock exchanges, including: ASX (MYX.AX), Frankfurt (HG6.F), Düsseldorf (HG6.DU), Hamburg (HG6.HM).
Mayne Pharma Group Ltd is an Australian pharmaceutical company headquartered in Salisbury, South Australia. It was founded in 2015 through the merger of Mayne Pharma Limited and Hospira Australia Pty Ltd. The company specializes in the development, manufacturing, and marketing of generic and specialized pharmaceutical products. Overall, the company operates in four main business segments: generics, specialized products, contract manufacturing, and distribution in the United States. Mayne Pharma's generics division produces a wide range of pharmaceutical products in various categories such as cardiology, gastroenterology, analgesics, and antibiotics. Mayne Pharma is also involved in the manufacture of generics with controlled release of active ingredients and long-acting generics. Mayne Pharma's specialized products are medicines used to treat rare or chronic diseases and often have higher added value than standard generics. This includes products in the fields of dermatology, oncology, endocrinology, urology, and psychiatry. Mayne Pharma also operates contract manufacturing, using its own infrastructure to manufacture products on behalf of third parties. Mayne Pharma's contract manufacturing offers both small and large molecule products. This option allows companies to manufacture their own products without having to build their own production and development system. In the United States, Mayne Pharma is involved in the distribution of pharmaceutical products and operates a distribution channel in the industry. This expands Mayne Pharma's portfolio with commercially attractive and acquired active ingredients and excipients. Mayne Pharma has a strong portfolio of products and assets to make it a leading provider of generic and specialized pharmaceuticals. The company also has a solid pipeline of compounds in various stages to support future growth. Mayne Pharma's success is based on a combination of high quality standards, competitive prices, a strong pipeline portfolio, and a dedicated strategic partnership with other companies in the industry. Mayne Pharma is focused on providing its customers with high quality and affordable medications and strengthening its leadership position in global markets.
The revenue of Mayne Pharma Group is 383.68 M AUD. This figure is based on current financial data and reflects the company's business performance.
The profit of Mayne Pharma Group is 24.47 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Mayne Pharma Group is currently 9.73. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Mayne Pharma Group stock.
The price-to-sales ratio (P/S) of Mayne Pharma Group is currently 0.62. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Mayne Pharma Group stock.
The Eulerpool Quality Score for Mayne Pharma Group is 3/10.
The ISIN of Mayne Pharma Group is AU000000MYX0. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Mayne Pharma Group is A1C821. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Mayne Pharma Group is MYX.AX. The ticker symbol is used to trade Mayne Pharma Group shares on the stock exchange.
Mayne Pharma Group stock
Mayne Pharma Group Peer Group
Mayne Pharma Group Ticker
Mayne Pharma Group FIGI
All fundamentals and in-depth analysis of Mayne Pharma Group
Our stock analysis for Mayne Pharma Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mayne Pharma Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.